BioTech
-
Insmed lung disease drug hits target in key Phase 3 trial
An experimental drug from Insmed Incorporated successfully reduced lung problems among patients with an airway disease in a closely watched…
Read More » -
Merus drug and Keytruda shrank tumors in patients with head and neck cancer
Merus said Tuesday that the combination of its experimental drug petosemtamab with the checkpoint inhibitor Keytruda shrank tumors in 62%…
Read More » -
Asahi Kasei to buy Calliditas, picking up kidney disease drug
LONDON — Seeking to build up its pharma business, the Japanese conglomerate Asahi Kasei is moving to buy Swedish biotech…
Read More » -
Do deaf people want a ‘cure’?
When Yilai Shu was training to be an otolaryngologist in Shanghai, in the mid 2000s, he often met parents with…
Read More » -
Duchenne drug from Nippon Shinyaku fails in rare confirmatory trial
Japanese drugmaker Nippon Shinyaku said on Monday that its Duchenne muscular dystrophy drug, Viltepso, part of a controversial class of…
Read More » -
BIO chaos, Ozempic, MDMA therapy, Guardant
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your…
Read More » -
Ozempic cut risk of death in diabetes patients with chronic kidney disease
Novo Nordisk’s Ozempic cut the risk of death in a trial of patients with type 2 diabetes and chronic kidney…
Read More » -
Guardant Health colon cancer test endorsed by FDA advisory panel
An independent panel of advisers to the Food and Drug Administration recommended the agency approve Guardant Health’s blood-based colon cancer…
Read More » -
J&J reports mixed data on next-generation radiopharmaceutical
An early-stage clinical trial of a radiopharmaceutical drug developed by Johnson & Johnson showed some signs of efficacy in prostate…
Read More » -
H5N1 bird flu vaccine, Cytokinetics, Gilead
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your…
Read More »